Immunome, Inc. $IMNM Holdings Cut by UBS Group AG

UBS Group AG lowered its holdings in Immunome, Inc. (NASDAQ:IMNM) by 47.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 307,194 shares of the company’s stock after selling 276,748 shares during the period. UBS Group AG’s holdings in Immunome were worth $6,599,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Assetmark Inc. bought a new position in Immunome in the third quarter worth about $39,000. BIT Capital GmbH bought a new position in Immunome in the third quarter worth about $69,000. BNP Paribas Financial Markets lifted its holdings in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Immunome in the third quarter worth about $76,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Insiders Place Their Bets

In other news, Director Philip Wagenheim sold 28,200 shares of Immunome stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $20.65, for a total transaction of $582,330.00. Following the sale, the director owned 341,147 shares of the company’s stock, valued at approximately $7,044,685.55. The trade was a 7.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jack Higgins sold 9,438 shares of Immunome stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total value of $204,238.32. Following the sale, the insider directly owned 22,000 shares in the company, valued at approximately $476,080. This trade represents a 30.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 139,438 shares of company stock worth $2,964,664. 7.21% of the stock is currently owned by corporate insiders.

Immunome Trading Down 1.2%

IMNM opened at $19.66 on Wednesday. The business’s 50 day moving average is $21.91 and its 200-day moving average is $21.27. The stock has a market cap of $2.23 billion, a PE ratio of -8.26 and a beta of 2.11. Immunome, Inc. has a twelve month low of $7.83 and a twelve month high of $27.65.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, analysts forecast that Immunome, Inc. will post -2.26 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Stephens cut their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Immunome in a report on Wednesday, May 13th. Craig Hallum raised their target price on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen raised shares of Immunome from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Immunome presently has an average rating of “Moderate Buy” and a consensus target price of $32.82.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.